Nazartinib
Product Specifications
Product Name Alternative
EGF816
UNSPSC Description
Nazartinib (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively.
Target Antigen
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/EGF816.html
Purity
99.03
Solubility
DMSO : ≥ 242 mg/mL
Smiles
O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4
Molecular Weight
495.02
References & Citations
[1]Lelais G, et al. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T79|[2]Jia Y, et al. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-12872/Nazartinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-12872/Nazartinib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1508250-71-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6286163-01 0.2 mL
CIDEA, CT (CIDEA, Cell death activator CIDE-A, Cell death-inducing DFFA-like effector A) (APC)
Ask
View Details MBS6286163-02 5x 0.2 mL
CIDEA, CT (CIDEA, Cell death activator CIDE-A, Cell death-inducing DFFA-like effector A) (APC)
Ask
View Details MBS1173682 Inquire
Recombinant Salmonella paratyphi C Large-conductance mechanosensitive channel (mscL)
Ask
View Details